HK1046846A1 - 包含boroproline的抗肿瘤复合物 - Google Patents

包含boroproline的抗肿瘤复合物 Download PDF

Info

Publication number
HK1046846A1
HK1046846A1 HK02106843.4A HK02106843A HK1046846A1 HK 1046846 A1 HK1046846 A1 HK 1046846A1 HK 02106843 A HK02106843 A HK 02106843A HK 1046846 A1 HK1046846 A1 HK 1046846A1
Authority
HK
Hong Kong
Prior art keywords
tumor agents
boroproline
agent
formula
cell proliferation
Prior art date
Application number
HK02106843.4A
Other languages
English (en)
Chinese (zh)
Inventor
P Wallner Barbara
Miller Glenn
Original Assignee
Point Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Point Therapeutics, Inc. filed Critical Point Therapeutics, Inc.
Publication of HK1046846A1 publication Critical patent/HK1046846A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02106843.4A 1999-05-25 2000-05-25 包含boroproline的抗肿瘤复合物 HK1046846A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13586199P 1999-05-25 1999-05-25
US60/135,861 1999-05-25
PCT/US2000/014505 WO2000071135A1 (en) 1999-05-25 2000-05-25 Anti-tumor comprising boroproline compounds

Publications (1)

Publication Number Publication Date
HK1046846A1 true HK1046846A1 (zh) 2003-01-30

Family

ID=22470056

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106843.4A HK1046846A1 (zh) 1999-05-25 2000-05-25 包含boroproline的抗肿瘤复合物

Country Status (6)

Country Link
EP (1) EP1187619A1 (enExample)
JP (1) JP2003500360A (enExample)
AU (1) AU781897B2 (enExample)
CA (1) CA2373643A1 (enExample)
HK (1) HK1046846A1 (enExample)
WO (1) WO2000071135A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
BR0114604A (pt) 2000-10-12 2003-10-14 Pharma Mar Sa Tratamento de c‰nceres
WO2003037373A1 (en) * 2001-10-31 2003-05-08 Medical Research Council Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer
JP4771661B2 (ja) * 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
JP2003267966A (ja) * 2002-03-13 2003-09-25 Pola Chem Ind Inc フラバン誘導体、皮膚線維芽細胞増殖抑制剤および皮膚外用剤
WO2004004661A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
JP4584245B2 (ja) 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9284337B2 (en) * 2011-11-22 2016-03-15 Trustees Of Tufts College Small molecule enhancer for dendritic cell cancer vaccines
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2018056907A1 (en) * 2016-09-21 2018-03-29 Agency For Science, Technology And Research Methods and compositions for inhibiting skin inflammation and determining cancer susceptibility
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
TWI812820B (zh) * 2018-12-10 2023-08-21 美商百歐克斯賽爾治療公司 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
CN115779148B (zh) * 2021-09-09 2024-02-23 中国科学院福建物质结构研究所 一种牙种植体表面涂层及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02268118A (ja) * 1989-04-07 1990-11-01 Mitsubishi Gas Chem Co Inc 免疫賦活剤
US5328936A (en) * 1993-02-01 1994-07-12 Rohm And Haas Company Polymerization process for making porous polymeric particles
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5767242A (en) * 1994-04-20 1998-06-16 Boehringer Ingelheim Int'l Gmbh Isolated dimeric fibroblast activation protein alpha, and uses thereof
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
US6100234A (en) * 1997-05-07 2000-08-08 Tufts University Treatment of HIV
AU765370B2 (en) * 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds
CA2339537A1 (en) * 1998-08-21 2000-03-02 Barbara Wallner Regulation of substrate activity

Also Published As

Publication number Publication date
AU5292700A (en) 2000-12-12
AU781897B2 (en) 2005-06-23
CA2373643A1 (en) 2000-11-30
JP2003500360A (ja) 2003-01-07
EP1187619A1 (en) 2002-03-20
WO2000071135A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
AU747599C (en) Antitumor agents
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
CA2291065A1 (en) Raf kinase inhibitors
MXPA04012965A (es) Inhibidores virales.
WO1999043355A3 (en) Formulations containing oxaliplatin
WO1999001118A3 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
CA2368618A1 (en) Method of enhancing the efficacy of anti-tumor agents
JPS5735516A (en) Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
PL342614A1 (en) Anticarcinogenic drugs
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
EP0724884A4 (en) INHIBITOR OF SIDE EFFECTS TO CANCER THERAPY
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
EP1109560A4 (en) COMPOUNDS USEFUL AS AICARFT INHIBITORS
WO2001008693A3 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
CA2283739A1 (en) Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
AU3360000A (en) Use of 4-amino pyridine for treatment of peripheral neuropathies
EP0378146A3 (en) Polyamine derivatives as antineoplastic agents
MXPA05006378A (es) Compuestos esteroides con actividad anti-tumoral.
YU43302A (sh) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija